【摘要】 目的观察吡格列酮对早期糖尿病肾病(DN)微量白蛋白尿(MAU)的影响。方法102例早期DN患者.将其随机分为2组。在常规降糖、有高血压者应用血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体阻滞剂(ARB)降压的基础上,治疗组加用吡格列酮15mg/d口服,连用12周。观察两组患者治疗前、后MAU、糖化血红蛋白(HbA1 c)、血压、血肌酐(SCr)变化。结果治疗组患者治疗前、后MAU均值差别有显著性意义(P<0.01),对照组患者治疗前、后MAU均值差别也有意义(P<0.01),治疗后治疗组与对照组MAU均值差别也有意义;治疗组中血压正常者治疗前、后的MAU在治疗组差别有意义,在对照组差别无显著性意义,治疗后治疗组与对照组MAU均值差别也有意义;伴高血压者治疗前、后的MAU在治疗组差别有意义,在对照组差别有意义,治疗后治疗组与对照组MAU均值差别也有意义。结论吡格列酮可明显减少早期糖尿病肾病患者的MAU,并与ACEI、ARB有协同保护肾脏作用。更多还原

【Abstract】 Objective To study the effects of pioglitazone on microalbuminuria(MAU)of early diabetic nephropathy(DN).Methods 102 patients of type 2 diabetes with DN were randomly divided into the control and the treatment group.The patients of DN with hypertension were used angiotensin converting enzyme inhibitors(ACEI) or angiotensin receptor blockers(ARB) treatment and pioglitazone 15mg/d,12 weeks.MAU,glycosylated hemoglobin(GHb,HbA1c),serum creatinine(SCr),blood pressure,were measured in the two groups before the treatment and 12 weeks after the treatment.Results After the treatment,MAU had been decreased significantly in the treatment group(P< 0.01) so does that of controls(P<0.01);If no ACEI or ARB treatment,MAU were not decreased significantly in the control group.Pioglitazone and ACEI/ARB were better than Pioglitazone only to decrease MAU.Conclusion Pioglitazone can obviously decrease MAU of patients with early DN,and coordinate with ACEI/ARB to protect kidney.更多还原